全文获取类型
收费全文 | 63893篇 |
免费 | 5346篇 |
国内免费 | 816篇 |
专业分类
耳鼻咽喉 | 346篇 |
儿科学 | 932篇 |
妇产科学 | 1151篇 |
基础医学 | 3130篇 |
口腔科学 | 969篇 |
临床医学 | 13892篇 |
内科学 | 5725篇 |
皮肤病学 | 553篇 |
神经病学 | 1429篇 |
特种医学 | 1193篇 |
外国民族医学 | 2篇 |
外科学 | 6629篇 |
综合类 | 8428篇 |
现状与发展 | 3篇 |
一般理论 | 7篇 |
预防医学 | 14840篇 |
眼科学 | 373篇 |
药学 | 7369篇 |
152篇 | |
中国医学 | 1296篇 |
肿瘤学 | 1636篇 |
出版年
2024年 | 148篇 |
2023年 | 1518篇 |
2022年 | 2615篇 |
2021年 | 3606篇 |
2020年 | 4029篇 |
2019年 | 3089篇 |
2018年 | 3028篇 |
2017年 | 2827篇 |
2016年 | 2664篇 |
2015年 | 2600篇 |
2014年 | 5617篇 |
2013年 | 5712篇 |
2012年 | 4470篇 |
2011年 | 4339篇 |
2010年 | 3602篇 |
2009年 | 3113篇 |
2008年 | 3008篇 |
2007年 | 2679篇 |
2006年 | 2393篇 |
2005年 | 1816篇 |
2004年 | 1502篇 |
2003年 | 1128篇 |
2002年 | 839篇 |
2001年 | 659篇 |
2000年 | 510篇 |
1999年 | 409篇 |
1998年 | 377篇 |
1997年 | 271篇 |
1996年 | 252篇 |
1995年 | 178篇 |
1994年 | 148篇 |
1993年 | 134篇 |
1992年 | 118篇 |
1991年 | 109篇 |
1990年 | 68篇 |
1989年 | 55篇 |
1988年 | 58篇 |
1987年 | 51篇 |
1986年 | 43篇 |
1985年 | 71篇 |
1984年 | 44篇 |
1983年 | 37篇 |
1982年 | 28篇 |
1981年 | 27篇 |
1980年 | 23篇 |
1979年 | 11篇 |
1978年 | 10篇 |
1977年 | 10篇 |
1975年 | 3篇 |
1973年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit
下载免费PDF全文
![点击此处可从《Asian Pacific journal of cancer prevention》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Sharareh SeifiBabak SalimiZahra Esfahani-MonfaredRamin RadmaneshSaeed YaghoubifardSara TalebianpourAdnan Khosravi 《Asian Pacific journal of cancer prevention》2022,23(4):1155-1158
Background: Thyrosin kinase inhibitors (TKIs) is approved for the first line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. This study performed to assess clinical effectiveness and safety of Erlova (generic form of Erlotinib). Methods: Somatic mutations of EGFR gene were studied in tumor tissue by polymerase chain reaction (PCR) and bi-directional sequencing in 513 chemonaive and histologically verified lung adenocarcinoma Iranian patients. Patients with EGFR mutation received Erlova at 150 mg/day as first line treatment. Primary endpoint was progression free survival (PFS). Results: About 21% (n=109) cases had EGFR mutation. Most EGFR mutations were occurred at exon 19. Among them, sixty nine patients treated with Erlova. Median PFS was 11.4 months and objective response rate (ORR) was about 88%. Most frequent treatment related adverse events was skin rash. Conclusion: Our findings showed Erlova had remarkable effectiveness. In mutation-positive patients with EGFR, Erlova can be used safely instead of other tyrosine-kinase inhibitors. 相似文献
5.
采用文献复习和实证研究经验的方法对《医疗质量管理办法》中涉及的医疗质量概念及相关问题进行探讨。《医疗质量管理办法》中的医疗质量的定义存在重大缺失,没有涉及医疗服务的结果,特别是患者安全。医疗质量的定义应与国际相关权威机构保持一致,应高度重视医疗服务的结果,特别是患者安全。 相似文献
6.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
7.
8.
《Journal of Radiology Nursing》2022,41(2):123-128
ObjectiveThe objective of this study was to reduce errors in a pathologic specimen with the help of a protocol systematizing the pathology specimen management process in the operating room.Materials and methodThis quasi-experimental study was carried out in the operating room unit of a research and training hospital. A protocol systematizing the process of specimen management in secure surgical pathology and prepared in light of the current literature was used as an intervention, and the effectiveness of the protocol was tested.ResultsIt was determined that the rate of adverse events decreased from .3226% (68 of 21,078) to .032% (6 of 18,706) after the protocol systematizing the surgical pathology specimen management process prepared by the researchers, and the protocol was found to be effective by 90% (P = .03).ConclusionBased on the data obtained in this study, we recommend the use of a pathologic specimen management protocol in the operating room. 相似文献
9.
10.